F
Clovis Oncology, Inc.
CLVSQ
OTC PK
E
Sell
3/14/2023Downgrade
Clovis Oncology, Inc. (CLVSQ) was downgraded to E+ from D on 03/14/2023.
Clovis Oncology, Inc. (CLVSQ) was downgraded to E+ from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Clovis Oncology, Inc. (CLVSQ) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
Clovis Oncology, Inc. (CLVSQ) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
Clovis Oncology, Inc. (CLVSQ) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, volatility index and growth index. The quick ratio declined from 0.97 to 0.11, operating cash flow declined 15.61% from -$35.13M to -$40.61M, and debt to equity increased from -1.77 to -1.59.
Clovis Oncology, Inc. (CLVSQ) was downgraded to E+ from D on 2/8/2023 due to a decline in the solvency index, volatility index and growth index. The quick ratio declined from 0.97 to 0.11, operating cash flow declined 15.61% from -$35.13M to -$40.61M, and debt to equity increased from -1.77 to -1.59.
D
Sell
5/16/2022Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Clovis Oncology, Inc. (CLVS) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 41.49% from -$41.34M to -$58.5M, and total revenue declined 4.78% from $35.97M to $34.25M.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, volatility index and total return index. Operating cash flow declined 41.49% from -$41.34M to -$58.5M, and total revenue declined 4.78% from $35.97M to $34.25M.
D
Sell
5/4/2022Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Clovis Oncology, Inc. (CLVS) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Clovis Oncology, Inc. (CLVSQ) was upgraded to D from E+ on 04/21/2022.
Clovis Oncology, Inc. (CLVSQ) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 1.8 to 1.41, and debt to equity increased from -2.67 to -2.22.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 1.8 to 1.41, and debt to equity increased from -2.67 to -2.22.
D
Sell
11/9/2021Upgraded
Clovis Oncology, Inc. (CLVSQ) was upgraded to D from E+ on 11/09/2021.
Clovis Oncology, Inc. (CLVSQ) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from -3.15 to -2.67.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D on 11/8/2021 due to a decline in the solvency index, volatility index and valuation index. Debt to equity increased from -3.15 to -2.67.
D
Sell
5/1/2020Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index and growth index. EBIT increased 5.5% from -$96.99M to -$91.66M, and total revenue increased 4.53% from $37.6M to $39.31M.
Clovis Oncology, Inc. (CLVS) was upgraded to D from D- on 5/1/2020 due to an increase in the valuation index and growth index. EBIT increased 5.5% from -$96.99M to -$91.66M, and total revenue increased 4.53% from $37.6M to $39.31M.
D
Sell
1/31/2019Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D- from E+ on 1/31/2019 due to an increase in the volatility index and total return index.
Clovis Oncology, Inc. (CLVS) was upgraded to D- from E+ on 1/31/2019 due to an increase in the volatility index and total return index.
E
Sell
1/16/2019Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D- on 1/16/2019 due to a decline in the volatility index and total return index.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D- on 1/16/2019 due to a decline in the volatility index and total return index.
D
Sell
9/15/2016Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D- from E+ on 9/15/2016 due to an increase in the volatility index and total return index.
Clovis Oncology, Inc. (CLVS) was upgraded to D- from E+ on 9/15/2016 due to an increase in the volatility index and total return index.
E
Sell
6/16/2016Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D- on 6/16/2016 due to a decline in the total return index and volatility index.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D- on 6/16/2016 due to a decline in the total return index and volatility index.
D
Sell
5/12/2016Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D- from E+ on 5/12/2016 due to an increase in the growth index and solvency index. Earnings per share increased from -$3.1195 to -$2.1741.
Clovis Oncology, Inc. (CLVS) was upgraded to D- from E+ on 5/12/2016 due to an increase in the growth index and solvency index. Earnings per share increased from -$3.1195 to -$2.1741.
E
Sell
4/21/2016Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D- on 4/21/2016 due to a noticeable decline in the total return index and volatility index.
Clovis Oncology, Inc. (CLVS) was downgraded to E+ from D- on 4/21/2016 due to a noticeable decline in the total return index and volatility index.
D
Sell
3/11/2016Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.69 to 0.93, and the quick ratio declined from 8.03 to 7.06.
Clovis Oncology, Inc. (CLVS) was downgraded to D- from D on 3/11/2016 due to a substantial decline in the total return index, volatility index and solvency index. Debt to equity increased from 0.69 to 0.93, and the quick ratio declined from 8.03 to 7.06.
D
Sell
1/4/2016Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 1/4/2016 due to a significant decline in the volatility index and total return index.
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 1/4/2016 due to a significant decline in the volatility index and total return index.
D
Sell
11/10/2015Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 11/10/2015 due to a noticeable increase in the solvency index, efficiency index and valuation index. Debt to equity declined from 1.44 to 0.69, total capital increased 44.06% from $487.17M to $701.82M, and net income increased 37.91% from -$71.53M to -$98.65M.
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 11/10/2015 due to a noticeable increase in the solvency index, efficiency index and valuation index. Debt to equity declined from 1.44 to 0.69, total capital increased 44.06% from $487.17M to $701.82M, and net income increased 37.91% from -$71.53M to -$98.65M.
D
Sell
6/12/2015Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 6/12/2015 due to a decline in the volatility index, efficiency index and solvency index. Debt to equity increased from 0.87 to 1.14, the quick ratio declined from 10.15 to 7.83, and total capital declined 12.77% from $619.13M to $540.09M.
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 6/12/2015 due to a decline in the volatility index, efficiency index and solvency index. Debt to equity increased from 0.87 to 1.14, the quick ratio declined from 10.15 to 7.83, and total capital declined 12.77% from $619.13M to $540.09M.
D
Sell
4/22/2015Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 4/22/2015 due to a major increase in the volatility index and total return index.
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 4/22/2015 due to a major increase in the volatility index and total return index.
D
Sell
12/18/2014Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 12/18/2014 due to a decline in the valuation index.
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 12/18/2014 due to a decline in the valuation index.
D
Sell
11/25/2014Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 11/25/2014 due to an increase in the valuation index.
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 11/25/2014 due to an increase in the valuation index.
D
Sell
11/10/2014Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 11/10/2014 due to a major decline in the solvency index, growth index and valuation index.
Clovis Oncology, Inc. (CLVS) was downgraded to D from D+ on 11/10/2014 due to a major decline in the solvency index, growth index and valuation index.
D
Sell
7/23/2014Downgrade
Clovis Oncology, Inc. (CLVS) was downgraded to D+ from C- on 7/23/2014 due to a decline in the total return index and volatility index.
Clovis Oncology, Inc. (CLVS) was downgraded to D+ from C- on 7/23/2014 due to a decline in the total return index and volatility index.
C
Hold
7/8/2014Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to C- from D+ on 7/8/2014 due to a large increase in the solvency index, valuation index and growth index.
Clovis Oncology, Inc. (CLVS) was upgraded to C- from D+ on 7/8/2014 due to a large increase in the solvency index, valuation index and growth index.
D
Sell
3/5/2014Upgraded
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 3/5/2014 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 44.09% from $345.53M to $497.89M, and net income increased 43.72% from -$20.32M to -$29.2M.
Clovis Oncology, Inc. (CLVS) was upgraded to D+ from D on 3/5/2014 due to a significant increase in the volatility index, total return index and efficiency index. Total capital increased 44.09% from $345.53M to $497.89M, and net income increased 43.72% from -$20.32M to -$29.2M.
